it Italiano
it Italiano

Who should be vaccinated for yellow fever

Who should be vaccinated for yellow fever

La libreria del viaggiatore:
volumi consigliati

Update: January 2023                                                                         Book your vaccination here

Vaccination against Yellow Fever (or Anti-Amharillic Vaccine), an acute viral disease transmitted by mosquito bite, is the only preventive practice that can be mandatorily required by a country’s health authorities in order to enter through border crossings. This occurs irrespective of the presence of manifest cases or epidemic outbreaks of the disease, but is an international provision designed to prevent the spread of the disease when the vector insect (Aedes aegypti) is still present in the country. The example is the Asian countries where the virus is absent but the vector, i.e. the mosquito, is present. Remember that Yellow Fever is a zoonosis (disease of animals – monkeys) that can be transmitted to humans through the bite of the Aedes type mosquito.

This is why vaccination is made compulsory in some cases, and in any case is strongly recommended in countries where the virus is present with the vector. It is necessary, before leaving for a country considered to be at risk, to find out about the international regulations adopted in this regard. Regardless of this, however, it is a good idea to check with experts where there is a real risk of infection or where the presence of infected animals is likely, and therefore in which cases vaccination is recommended before travelling. Currently, the areas at risk of transmission are in Central and South America, as well as in many countries in Africa. In Asia, the presence of this virus is not reported.

Vaccination is risk-free; it rarely produces a fever after 24 hours at most, which is easily controlled with antipyretics
It is not recommended for individuals allergic to egg proteins.
Can be administered from the age of 6 months.
Use during pregnancy: not recommended.

Period of activity of the live attenuated virus once injected with the vaccine

During the first 48/72 hours, the live attenuated virus, which is harmless to the organism, reproduces and activates the defence system, simulating the disease. The immunological cellular part is activated and anti-virus antibodies (neutralising the virus) are formed. This fact serves to disprove the urban legend that the harmful action of the ‘live attenuated virus’ present in the vaccine is active for 3 or even 6 months (one cannot conceive for this length of time). It is reiterated that already after two to three days the virus is neutralised by the immune response, which reaches its maximum cellular response as early as the seventh day. Its action therefore on the product of conception is practically non-existent. Therefore, all women who think they might become pregnant in the immediate future can be vaccinated without any problem after vaccination.

To learn about the disease please visit our disease fact sheet on Yellow Fever.

To find out about the vaccination please visit our Yellow Fever vaccination factsheet

If you would like further information, please contact us by e-mail at seg.cesmet@gmail.com or phone +39 06/39030481, or whatsapp +393466000899

Ultimi articoli pubblicati nel blog Ultim'ora

ChatGPT

ChatGPT è un software di intelligenza artificiale che può dialogare via internet con l’utente su vari argomenti Per le vostre prove ChatGPT …

Leggiamo e riportiamo (traduzione automatica) da: scitechdaily.com Quali sono le chiavi per un invecchiamento “di successo” o ottimale? Un nuovo studio ha …

malaria

Leggiamo e riportiamo (traduzione automatica) dal sito web di BioNTech: BioNTech avvia la sperimentazione clinica di fase 1 per il vaccino contro …

Le zanzare geneticamente modificate per fermare le malattie superano i primi test. di Lisa Rapaport da: medscape.com Le zanzare geneticamente modificate rilasciate …

error: Il contenuto di questo sito è protetto!
C e s m e t . c o m C l i n i c a d e l V i a g g i a t o r e
C e s m e t . c o m C l i n i c a d e l V i a g g i a t o r e